Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects both pancreatic ß-cell survival as well as ß-cell secretory function. These medications do not incite ...

[7] Because the human brain is not accessible to sampling, much of what we have learned about the mechanism of action of bromocriptine has been derived from animal studies. A large body of ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

A multicenter collaboration has identified a potential new treatment for an aggressive sarcoma arising in the nerves. The ...